Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C? by Clem, James R et al.
© 2010 Clem et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Risk Management and Healthcare Policy 2010:3 1–11
Risk Management and Healthcare Policy

R e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
individualized initiation of statin therapy 
determined by baseline LDL-C: Are you more 
likely to achieve goal LDL-C?
James R Clem1 
Joe D Strain2 
Debra K Farver3
1South Dakota State University 
College of Pharmacy Sioux Falls, 
South Dakota, USA; 2South Dakota 
State University College of Pharmacy, 
Rapid City Regional Hospital, Rapid 
City, South Dakota, USA; 3South 
Dakota State University College of 
Pharmacy, Yankton, South Dakota, USA
Correspondence: James Clem 
Professor of Pharmacy Practice and 
Department Head, South Dakota State, 
University College of Pharmacy, 4801 
North Career Avenue, Sioux Falls, 
SD 57107, USA 
Tel +1 605-367-5637 
Fax +1 1-605-782-3218 
email james.clem@sdstate.edu
Abstract: Cardiovascular disease remains the leading cause of death in the world. A significant 
amount of clinical data are available to demonstrate the positive influence that 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitor (statin) therapy has on slowing the progression 
of cardiovascular disease and improving clinical outcomes. Achieving the treatment goals for 
cholesterol in cardiovascular disease continues to present challenges. Recent clinical trial infor-
mation is available assessing the use of more aggressive initial doses of statin therapy based 
on initial low-density lipoprotein cholesterol (LDL-C) measurements in an attempt to reach 
treatment goals sooner. Six clinical trials assessed low-, moderate- and high-risk individuals 
as well as those with type 2 diabetes mellitus to determine if this treatment approach is both 
safe and effective. The studies concluded that initial dosing of statin therapy determined by a 
baseline LDL-C measurement demonstrates good achievement in reaching treatment goals and 
does not result in a higher rate of adverse effects.
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Introduction
Cardiovascular disease continues to be the leading cause of death worldwide and coro-
nary heart disease (CHD) accounted for approximately 7.6 million deaths in 2005.1 
Research has revealed that increased low-density lipoprotein cholesterol (LDL-C) 
significantly contributes to this disease process.2 Based on these data the National 
Cholesterol Education Program (NCEP) and the Joint European Societies emphasize 
LDL-C lowering as a critical step in the management of CHD.2,3 Recommendations 
state goal LDL-C level is 100 mg/dL for patients with a history of CHD and for 
patients having what is considered a risk equivalent to CHD.2,3 More recent data suggest 
that although there is strong evidence for a goal LDL-C of 100 mg/dL practitioners 
should consider a goal of 70 mg/dL for the highest-risk patients.4,5 Diabetes mel-
litus is identified as one of the risk equivalents to CHD and the American Diabetes 
Association endorses the goal LDL-C level of 100 mg/dL for diabetes patients and 
further states that a goal of 70 mg/dL should be considered for diabetes patients 
with CHD.2,3,6
LDL-C lowering is frequently achieved through the use of 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors (statins). The degree to which statins 
lower LDL-C varies based on the statin and the dose utilized.7,8 Current treatment guide-
lines suggest statin dosing consists of starting an initial dose and then titrating the dose 
in 6 weeks if the goal LDL-C is not obtained.2 The largest percentage of statin-induced 
LDL-C reduction is seen with suggested standard doses. An approximate 6% additional Risk Management and Healthcare Policy 2010:3 
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reduction is achieved each time the dose is doubled, which 
may allow a patient to achieve their ultimate goal LDL.4,8 
Dose titration in patients not meeting goal depends on proper 
follow-up by the patient and practitioners. Surveys of lipid-
lowering therapy have suggested a significant percentage of 
patients are not properly managed. The EUROASPIRE II trial 
conducted from 1999 to 2000 revealed that of the patients 
needing lipid-lowering therapy (91.7% on statins) only 49% 
achieved their cholesterol goal.9 More recent surveys in other 
European countries have also demonstrated a significant por-
tion of patients are not reaching goal. The CEPHUS survey 
revealed 58.5% of patients met the goal LDL-C, with 82.5% 
of the patients taking statins.10 High-risk patients needing to 
achieve a goal LDL-C of 100 mg/dL may pose a problem 
if their initial LDL-C is significantly elevated. A survey of 
high-risk patients in a London-based practice showed 38.8% 
of patients on a statin reached goal LDL.11 Although it should 
be noted the goal LDL was 2.0 mmol/L [77 mg/dL] based 
on the Joint British Societies’ guidelines.11,12
Concerns about failing to appropriately titrate statins to 
goal have led to proposals of utilizing higher doses of statins 
as initial therapy.7 Data have shown that utilizing higher ini-
tial doses of atorvastatin allows more patients to reach their 
goal LDL-C without compromising safety.7 Other data have 
revealed that high dose atorvastatin 80 mg/day has morbidity 
and mortality benefits vs pravastatin 40 mg/day.13 A meta-
analysis further showed that greater LDL-C lowering was 
associated with a lower number of cardiovascular events.14
Based on these data and the concern for patients not meet-
ing goal LDL-C, it seems prudent to be more aggressive with 
initial statin dosing and select the initial starting statin dose 
based on the degree of LDL-C lowering required in each indi-
vidual patient. Recently several studies have been conducted 
that utilize dosing algorithms to select the starting dose of 
atorvastatin. Atorvastatin has been shown to reduce LDL-C 
levels by 39% to 60% depending on the dose, which ranges 
from 10 to 80 mg daily.15 These algorithms select the starting 
dose based on the patients’ baseline LDL and/or CHD risk. 
This paper reviews these studies and provides discussion on 
the potential utility of such protocols in clinical practice. The 
first group of studies evaluates a range of high-risk and low-
risk patients, whereas the second group of studies specifically 
focuses on the high-risk diabetes population.
Data sources
A literature search was conducted using the terms lipid-
lowering medications, individualized dosing, algorithm-
based dosing of statins, simvastatin, pravastatin, lovastatin, 
rosuvastatin, atorvastatin, and fluvastatin. MEDLINE, 
BIOSIS, EBSCOhost, and OVID databases were primary 
search sites from 2000 to August 2009. All English-based 
articles and abstracts obtained from the literature searches 
were reviewed. Additional information was obtained from 
references cited in the articles.
Clinical evidence
The initial study evaluating use of treatment algorithms 
with statins was the Atorvastatin Goal Achievement Across 
Risk Levels (ATGOAL) trial.16 The baseline characteristics 
and study design of the ATGOAL trial, as well as the other 
studies reviewed, are summarized in Table 1. ATGOAL was 
an 8-week study with a primary endpoint of determining the 
percentage of patients who reached the LDL-C target with 
starting doses of atorvastatin based on the baseline LDL-C 
and CHD risk category. All lipid-lowering medications were 
discontinued 8 weeks prior to the study. Baseline lipid pro-
files were obtained after the washout period. Patients were 
given atorvastatin (dose range 10 to 80 mg/day) based on the 
LDL-C and risk categories (Table 2). A single dose titration 
at 4 weeks was available for patients who did not achieve 
their goal. At 8 weeks, 84.8% (1031/1216) of patients 
attained their LDL-C target. At 4 weeks, the percentage of 
patients achieving the LDL-C target was 84.2% (1049/1246). 
When analyzing the risk categories at 8 weeks, the attain-
ment of goal was 92.9% (299/322) in the low risk group as 
compared to 84% (199/237) in the medium risk group and 
81.1% (533/657) in the high risk group (Table 3). Of the 
patients completing the study 156 were eligible for a dose 
titration at week 4; however only 110 of these patients actu-
ally had their dose increased with the remainder staying on 
the original dose per physician discretion. The secondary 
outcomes are listed in Table 4. A total of 225 patients had 
an adverse event and 52 (4%) discontinued atorvastatin due 
to the adverse event. The discontinuation rates for possible, 
probable or definitely related adverse events were 0.6%, 
1.6% and 5.1% in the low-risk, medium-risk and high-
risk groups, respectively. Less than 1% had an aspartate 
aminotransferase (AST) and/or alanine aminotransferase 
(ALT) elevation greater than 3 times upper limits of normal 
and there were no documented cases of creatine phospho-
kinase (CPK) elevation greater than 10 times upper limits 
of normal.
Two trials were designed using the same methodology 
but studied patients in different geographical areas.17,18 The 
Achieve Cholesterol Targets Fast with Atorvastatin Stratified 
Titration (ACTFAST)-1 study was conducted in Canada and Risk Management and Healthcare Policy 2010:3 
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Table  Clinical trials: study design and patient demographics16–21
  ATGOAL6 ACTFAST -7 ACTFAST -8 Ducobu et al9 Atorvastatin 
Study Group in 
Korea0
Ferrer-Garcia 
et al
Study design Multicenter, 
open-label, 
single-step  
titration
Multicenter 
prospective, 
open-label, single 
dose titration
Multicenter, 
prospective, open-
label, single dose 
titration
Multicenter, 
prospective, 
open-label, single 
dose titration
Multicenter, 
prospective, 
open-label, single 
dose titration in 
type 2 diabetes
Prospective, no dose 
titration, type 2 
diabetes
Study duration 8 weeks 12 weeks 12 weeks 12 weeks 8 weeks 24 weeks
inclusion criteria Men or non-
pregnant women 
between of 
18–80 years, 
baseline LDL-C 
5.6 mmol/L 
(220 mg/dL), 
TG  600 mg/dL, 
and capable of 
maintaining life-
style and dietary 
modifications
Men or women at 
least 18 years of 
age with diagnosed 
hyperlipidemia and 
a LDL-C  
 2.6 mmo/L 
(100 mg/dL) along 
with a screening 
LDL-C  
 5.7 mmol/L 
(220 mg/dL), 
TG level  
of 6.8 mmol/L  
(600 mg/dL) and 
were considered 
high risk based on 
history CHD, CHD 
equivalent, or 
estimated 10-year 
CHD risk 20%
Men or women at 
least 18 years of 
age with diagnosed 
hyperlipidemia and 
a LDL-C  
 2.6 mmo/L 
(100 mg/dL) along 
with a screening 
LDL-C  
 5.7 mmol/L 
(220 mg/dL),  
TG level 
of 6.8 mmol/L 
(600 mg/dL) and 
were considered 
high risk based on 
history CHD, CHD 
equivalent, or 
estimated 10-year 
CHD risk 20%
LDL-C of 
3.0–6.1 mmol/L 
(115–235 mg/dL) 
after 3 months 
of lipid-lowering 
diet, TG level 
400 mg/dL, ages 
30–80 years, and 
were high CHD 
risk
Men or women of 
18–80 years with 
hyperlipidemic 
type 2 diabetes, 
LDL-C  
 130 mg/dL or 
glycated hemo-
globin 10% and 
TG  400 mg/dL 
at baseline
Patients were at least 
18 years old, had 
a glycated hemo-
globin of 10%, 
TG  6.8 mmol/L 
(600 mg/dL) and had 
a baseline LDL-C 
of 2.6 mmol/L 
(100 mg/dL) despite 
6 to 12 weeks of 
dietary treatment
Mean age (years) 55.1 low-risk 
58.8 medium-risk 
61.6 high-risk
63 61.2 62.1 58.4 61.1
Gender (%)
Male 58 68 61 70.2 28.9 59.9
Female 42 32 39 29.8 71.1 40.1
Smokers NR 21% 22.7% 23.3% NR 29.7%
Diabetes 44% in the high-
risk group only
39% 32.7% 34.4% 100% 100%
History of CHD 54% in the high-
risk group only
61% 67% 61.9% NR NR
Mean baseline 
LDL-C mmol/L 
(mg/dL)
4.8 (187) low-risk  
4.6 (176) 
medium-risk  
4.1 (160) high-risk
3.9 (151) in 
statin-free group 
3.5 (135) in the 
statin-treated 
group
4.1 (159) in 
statin-free group 
3.8 (147) in 
statin-treated 
group
4.1 (158) 160.3 ± 22.4 4.10 ± 0.75
Abbreviations: NR, not reported; LDL-C, low-density lipoprotein cholesterol;   TG, triglycerides; CHD, coronary heart disease.
Western Europe, while the ACTFAST-2 study was in northern 
and eastern Europe.17,18 The primary outcome was to assess 
achievement of LDL-C goal (2.6 mmol/L [100 mg/dL]), 
in high-risk patients, with starting doses of atorvastatin (dose 
range 10 to 80 mg/day) based on the initial LDL-C baseline 
value with or without a single dose titration at 6 weeks. At 
6 and 12 weeks, the secondary outcomes evaluated were 
the percentage of patients reaching a total cholesterol/high 
density lipoprotein-cholesterol (TC/HDL-C) ratio 4 and 
mean percent change in TC, LDL-C, HDL-C, TC/HDL-C 
ratio, non-HDL-C, triglycerides (TG), and apolipoprotein-
B (apo-B). Safety of atorvastatin was also monitored. The 
individuals agreed to follow a diet plan. Exclusion criteria 
was use of a nonstatin lipid-lowering medication in the last Risk Management and Healthcare Policy 2010:3 
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Table  Clinical trials: initial dosing protocols of atorvastatin16–21
Baseline  
LDL-C mmol/L  
(mg/dL)
ATGOAL study6
Low-risk category Medium-risk  
category
High-risk category
 CHD risk factor  risk factors  
with 0-year CHD  
risk 0%
 risk factors with  
0-year CHD risk  
0%–0%
CHD, CHD equivalent,  
 risk factors with  
0-year CHD risk 0%
2.6–3.3 (100–129) NA NA NA 10 mg
3.4–3.6 (130–139) NA NA 10 mg 10 mg
3.6–3.9 (140–149) NA NA 10 mg 10 mg
3.9–4.1 (150–159) NA NA 10 mg 20 mg
4.1–4.4 (160–169) 10 mg 10 mg 10 mg 40 mg
4.4–4.6 (170–179) 10 mg 10 mg 10 mg 80 mg
4.7–4.9 (180–189) 10 mg 10 mg 20 mg 80 mg
4.9–5.7 (190–220) 10 mg 20 mg 20 mg 80 mg
Target LDL-C 4.1 mmol/L  
(160 mg/dL)
3.4 mmol/L  
(130 mg/dL)
3.4 mmol/L  
(130 mg/dL)
2.6 mmol/L  
(100 mg/dL)
ACTFAST  and  studies7,8
Baseline LDL-C mmol/L (mg/dL) Statin-free group Statin-treated group
2.6–3.8 (100–149) 10 mg 20 mg
3.9–4.1 (150–159) 20 mg 40 mg
4.2–4.4 (160–169) 40 mg 80 mg
4.5–5.7 (170–220) 80 mg 80 mg
Ducobu et al9
Baseline LDL-C mmol/L (mg/dL) Statin-naïve patients Statin-treated patients
3.0–4.2 (115–164) 10 mg 20 mg
4.3–4.5 (165–174) 20 mg 40 mg
4.5–6.1 (175–235) 40 mg 40 mg
Atorvastatin study group in Korea0
Baseline LDL-C mmol/L (mg/dL)
130–149 10 mg
150–159 20 mg
160 40 mg
Ferrer-Garcia et al
Baseline LDL-C mmol/L (mg/dL) Dose Target reduction in LDL-C level (%)
2.6–3.8 (100–147) 10 mg 38
3.9–4.1 (151–159) 20 mg 46
4.2–4.39 (162–170) 40 mg 51
4.40 (170) 80 mg 54
Abbreviations: CHD, coronary heart disease; NA, not-applicable; LDL-C, low-density lipoprotein cholesterol.
2 months, doses of 40 mg/day of any statin and current 
use of atorvastatin. Patients were divided into a statin-free 
group (no prior statins within the past 2 months) or a statin-
treated group (currently receiving a statin but not achieving 
LDL-C target goal). The dose assignment of atorvastatin is 
listed in Table 2.
The ACTFAST-1 study had 1345 patients in the statin-free 
group and 772 in the statin-treated group.17 At 12 weeks, 
79.6% of statin-free patients achieved the LDL-C target 
as compared to 58.7% of statin-treated patients. Of those 
that achieved the target LDL-C goal (n = 1071), 90% in 
the statin-free group did so with their initial dose. Of the Risk Management and Healthcare Policy 2010:3 
individualized initiation statin doses based on LDL-C Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Table  Primary study outcomes16–21
Clinical trial Treatment groups Proportion of subjects meeting goal (%) (9% CI)
LDL-C
6 weeks 8 weeks  weeks  weeks
ATGOAL16 Low risk (n = 322) NR 92.9 NR NR
Medium risk (n = 237) NR 84.0 NR NR
High risk (n = 657) NR 81.1 NR NR
ACTFAST-117 Statin-free (n = 1345)
Atorvastatin 10 mg 84.3 (81.5–87.0) NR 83.1 (80.3–86.0) NR
Atorvastatin 20 mg 83.4 (78.0–88.8) NR 80.7 (74.9–86.5) NR
Atorvastatin 40 mg 88.9 (83.9–93.9) NR 82.2 (76.2–88.2) NR
Atorvastatin 80 mg 79.9 (75.3–84.4) NR 72.1 (67.0–77.2) NR
Statin-treated (n = 772)
Atorvastatin 20 mg 55.1 (51.0–59.2) NR 60.3 (56.3–64.3) NR
Atorvastatin 40 mg 55.4 (44.1–66.7) NR 60.3 (49.1–71.5) NR
Atorvastatin 80 mg 58.1 (48.7–67.5) NR 50.9 (41.5–60.4) NR
ACTFAST-218 Statin free (n = 341 at wk 6; n = 345 
at week 12)
Atorvastatin 10 mg 77.8 (71.0–84.6) NR 75.0 (67.9–82.1) NR
Atorvastatin 20 mg 82.0 (71.4–92.7) NR 78.0 (66.5–89.5) NR
Atorvastatin 40 mg 86.5 (71.2–95.5) NR 79.5 (66.8–92.2) NR
Atorvastatin 80 mg 69.1 (60.5–77.7) NR 68.2 (59.4–77.1) NR
Statin-treated (n = 249 at week 6;  
n = 253 at week 12)
Atorvastatin 20 mg 52.4 (44.3–60.5) NR 67.8 (60.2–75.4) NR
Atorvastatin 40 mg 60.7 (42.6–78.8) NR 62.1 (44.4–79.7) NR
Atorvastatin 80 mg 48.1 (36.9–58.2) NR 46.8 (35.6–57.9) NR
Ducobu et al19 Statin-naïve (n = 215)
Atorvastatin 10 mg NR NR NR NR
Atorvastatin 20 mg NR NR 95.7 NR
Atorvastatin 40 mg NR NR 95.6 NR
Korea study20 (n = 149)
Atorvastatin 10 mg NR 87.5 NR NR
Atorvastatin 20 mg NR 86.4 NR NR
Atorvastatin 40 mg NR 93.9 NR NR
Atorvastatin 80 mg NR 66.7 NR NR
Ferrer-Garcia et al21 (n = 202)
Atorvastatin 10 mg NR NR NR 75
Atorvastatin 20 mg NR NR NR 67
Atorvastatin 40 mg NR NR NR 51
Atorvastatin 80 mg NR NR NR 59
Abbreviations: LDL-C, low-density lipoprotein cholesterol; NR, not reported.
435 patients reaching goal in the statin-treated group, the 
target LDL-C was achieved with atorvastatin at 20 mg 
(72%), 40 mg (64%) and 80 mg (96%). In the patients reach-
ing goal in the statin-free group, titration was necessary with 
the doses of 10 mg (n = 106), 20 mg (n = 30) and 40 mg 
(n = 17) and target LDL-C was achieved in 58%, 67% and 
69%, respectively. Dose titration was needed in the statin-
treated group with target LDL-C achieved in 42% with the 
initial dose of 20 mg (n = 260) and 52% with the initial dose 
of 40 mg (n = 33). Of note, up to 20% of patients in each Risk Management and Healthcare Policy 2010:3 6
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Table  Secondary study outcomes16–21
Clinical trial Treatment groups Percentage mean reduction of lipid parameters from baseline Proportion of 
subjects
LDL-C TC TG HDL-C TC/HDL-C Apo-B Non-HDL-C TC/HDL-C 
ratio target 
ATGOAL16 Low-risk group (n = 335) -39.1 -29.0 -18.6 -2.2 NR NR -31.2 NR
8-week Medium-risk group (n = 249) -36.8 -28.7 -20.9 1.7 NR NR -31.4 NR
results High-risk group (n = 699) -44.6 -35.0 -23.5 -2.4 NR NR -34.4 NR
ACTFAST-117 
12-week results
Statin-free (n = 1345)
Atorvastatin 10 mg -34.8 -23.9 -13.7 3.1 -25.4 -31.5 -32.1 83.1
Atorvastatin 20 mg -43.8 -31.6 -22.7 1.4 -32.0 -39.4 -41.0 85.9
Atorvastatin 40 mg -49.8 -37.2 -26.5 1.6 -37.4 -44.8 -47.1 86.9
Atorvastatin 80 mg -52.7 -39.7 -5.2 0.6 -39.1 -46.8 -48.7 79.1
Statin-treated (n = 772)
Atorvastatin 20 mg -21.4 -15.3 -8.2 1.0 -15.4 -21.2 -20.4 79.3
Atorvastatin 40 mg -37.0 -27.5 -22.8 0.6 -27.3 -34.2 -35.2 78.4
Atorvastatin 80 mg -41.0 -32.0 -18.9 -2.7 -29.5 -38.0 -39.1 70.6
ACTFAST-218 
12-week results
Statin-free (n = 347)
Atorvastatin 10 mg -33.6 -23.6 -9.9 4.2 -24.6 -31.6 -31.2 77.8
Atorvastatin 20 mg -40.5 -28.4 -12.3 2.3 -29.3 -36.0 -36.8 80.8
Atorvastatin 40 mg -49.1 -36.4 -15.0 -3.7 -32.9 -44.3 -45.1 84.6
Atorvastatin 80 mg -49.4 -39.2 -21.9 -3.2 -36.3 -44.5 -47.1 75.0
Statin-treated (n = 253)
Atorvastatin 20 mg -24.7 -17.4 -3.8 -2.7 -13.3 -22.5 -21.9 71.2
Atorvastatin 40 mg -36.6 -27.0 -19.9 4.1 -28.3 -33.1 -34.8 82.8
Atorvastatin 80 mg -40.2 -30.8 -19.5 -1.4 -29.1 -36.3 -37.7 66.7
Ducobu et al  
12-week results19
Statin-naïve (n = 215) 
(Data NR based on dose)
-45.9 -32.4 NR 0.04 NR NR NR NR
Korea study  
8-week results20
Atorvastatin 10 mg (n = 56) -42.5 -30.3 -19.3 2.8 NR NR -38.9 NR
Atorvastatin 20 mg (n = 22) -52.9 -37.5 -32.6 4.0 NR NR -49.4 NR
Atorvastatin 40 mg (n = 65) -58.7 -45.0 -20.9 -5.2 NR NR -53.0 NR
Atorvastatin 80 mg (n = 6) NR NR NR NR NR NR NR NR
Ferrer-Garcia 
et al21
 
Atorvastatin 10 mg (n = 75)
 
-16.5
 
-21.6
 
-12.3
 
-3.0
 
NR
 
NR
 
-27.1
 
NR
24-week results Atorvastatin 20 mg (n = 61) -35.6 -28.5 -18.0 -1.8 NR NR -36.7 NR
Atorvastatin 40 mg (n = 35) -35.5 -29.8 -26 -0.2 NR NR -38.2 NR
Atorvastatin 80 mg (n = 17) -55.7 -49.0 -32.5 -7.2 NR NR -56.7 NR
Abbreviations: NR, not reported; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; TC/HDL-C, 
total cholesterol/low-density lipoprotein-cholesterol; Apo-B, apolipoprotein B; non-HDL-C, non-high-density lipoprotein cholesterol.
group that met criteria for dose titration did not actually 
receive an increased dose. Reasons why some patients 
did not have a dose titration were failure of investigator to 
follow protocols (n = 23), patient not following directions 
(n = 28) and adverse events (n = 7). The primary and sec-
ondary efficacy outcomes are summarized in Tables 3 and 4. 
The incidence of adverse events with all doses of atorvastatin 
was 12.1%.Adverse events were asthenia (1.6%), myalgia 
(1.4%), constipation (1.1%), dyspepsia (1.1%), elevated 
AST/ALT  3 times upper limit, regardless of causality 
(1.2%), and one case of elevated CPK  10 times the upper 
limit of normal. Of note, this patient did not report myalgia Risk Management and Healthcare Policy 2010:3 7
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and had 2 falls 2 days prior due to a previous condition 
unrelated to statin therapy.
The ACTFAST-2 study results revealed 73.5% of 
patients in the statin-free group (n = 347) and 60.5% in the 
statin-treated group (n = 253) achieved the LDL-C target 
at 12 weeks.18 At week 6, 391 patients had attained the pri-
mary outcome. The majority of subjects who reached goal 
achieved the target LDL-C by week 6 (96%). Dose titration 
results were not reported because so few subjects met criteria 
for dose titration. The primary and secondary outcomes are 
summarized in Tables 3 and 4. The most frequently reported 
adverse events were diarrhea (0.5%), nausea (0.5%), elevated 
AST/ALT (0.8%) and myalgia (0.7%). Twelve patients dis-
continued therapy.
The primary endpoint of the 12-week study by Ducobu 
et al was to determine the proportion of patients achieving 
their LDL-C goal with starting doses of atorvastatin (10 to 
40 mg/day) based on LDL-C levels.19 A single dose titration 
was allowed at week 6 by doubling the dose of atorvastatin if 
the goal LDL-C was not obtained. Secondary endpoints were 
mean percentage change in TC, LDL-C, HDL-C, and TG at 
weeks 6 and 12 along with proportion concomitantly reaching 
LDL-C and TC targets at week 12. Other secondary endpoints 
assessed were the proportion of  patients reaching goal LDL-C 
at 6 weeks along with different LDL-C strata achieving 
LDL-C control at 6 and 12 weeks, proportion of diabetes 
patients achieving LDL-C control at 12 weeks and C-reactive 
protein (CRP) at baseline and at weeks 6 and 12. All patients 
were counseled on the Therapeutic Lifestyle Changes diet.2 
Medication-related exclusion criteria was use of nonstatin 
lipid-lowering medications (fibrates, resins, or acipimox) 
or atorvastatin during the last two months and higher 
maintenance doses of other statins such as 40 mg/day of 
simvastatin, fluvastatin or pravastatin. Patients were divided 
into two treatment groups; statin-naïve (n = 215) and previ-
ously treated with a statin (n = 11). Due to the low overall 
number of patients in the previous statin treatment arm, 
the results in those subjects were not reported. Dosing of 
atorvastatin is listed in Table 2. In the statin-naïve group, 
95.4% (95% CI 91.4% to 97.9%) reached their LDL-C goal 
at 6 weeks. Dose titration was required in 4.6% of patients. 
At 12 weeks, 96.4% (95% CI 92.7% to 98.5%) of the statin-
naïve group reached the goal. Response rates did not vary 
based on the different starting dose subgroups. A second-
ary endpoint reported, with the statin-naïve group, was a 
mean standard deviation change in CRP of –1.7 (9.3) mg/L 
and -1.4 (9.1) mg/L at weeks 6 and 12, respectively. The 
mean percentage standard deviation change in the CRP was 
5.2 (156.1) and 29.4 (253.8) at weeks 6 and 12. At 12 weeks, 
97.1% of diabetes patients reached the LDL-C goal as com-
pared to 95.6% of the nondiabetes patients. Overall 32.8% of 
patients reported an adverse event with headache, abdominal 
pain, diarrhea, and upper respiratory infection being the 
most commonly reported, occurring in 2.2% of patients. 
Although 3.4% of patients withdrew from the study due to 
an adverse event, no serious adverse events were related to 
atorvastatin treatment.
Clinical evidence in type  
diabetes patients
The Atorvastatin Study Group in Korea evaluated the flexible 
dosing of atorvastatin (dose range 10 to 40 mg/day) based 
on the LDL-C in type 2 diabetes patients.20 The primary 
outcome was the percentage of patients meeting the goal 
LDL-C of 100 mg/dL following 8 weeks of therapy. Additional 
measurements were the percentage change over 8 weeks 
in HDL-C, TG, TC, non-HDL, ratio of LDL to HDL and 
non lipid-lowering effects such as flow-mediated endothelium-
dependent dilation (FMD), flow-mediated endothelium inde-
pendent dilation (EID) and plasminogen activator inhibitor 
type 1 (PAI-1). A 4-week washout period was done with any 
lipid-lowering agent prior to enrollment. Baseline lipid param-
eters and glycated hemoglobin were obtained. Medication-
related exclusion criteria were previous use of niacin or 
fibrates. Continuation of the patient’s diet and exercise plan 
was recommended during the study. The atorvastatin dosing 
protocol is listed in Table 2. At the end of 4 weeks, a dose 
titration could occur if the target LDL-C of 100 mg/dL was 
not met. Of the 209 enrolled patients, 149 completed the study. 
At 4 weeks, the percentage of patients reaching LDL-C goal 
was 90.3%, 88.9% and 91.3% when receiving 10 mg, 20 mg 
and 40 mg, respectively. At 8 weeks, the overall percentage 
of patients attaining the goal was 89.3% (95% CI 84.3% 
to 94.2%, Chi-square test P = 0.1722). Fourteen patients 
(9.4%) had a dose titration at 4 weeks. A dose-dependent 
statistically significant decrease occurred with LDL-C, TG 
and non-HDL-C (P  0.0001). The pre- and post-treatment 
values for FMD improved (P = 0.0001) but the EID and PAI-1 
did not reach statistical significance. The initial 209 patients 
were analyzed for safety of atorvastatin. Adverse events were 
abdominal pain (2.9%), increased ALT (2.4%), dizziness 
(1.9%), headache/dyspepsia (1.4%), and increased CK 
(1.4%). Ten patients withdrew from the study due to adverse 
events, but no events were reported to be serious.
Ferrer-Garcia et al studied the dose assignment of 
atorvastatin (10–80 mg/day) to the baseline LDL-C in Risk Management and Healthcare Policy 2010:3 8
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statin-naïve type 2 diabetes patients.21 The primary efficacy 
outcome, at 24 weeks, was the percent of patients achiev-
ing the LDL-C target of less than 2.6 mmol/L (100 mg/dL) 
without a dose titration. The mean percent change in TC, 
LDL-C, HDL-C, non-HDL-C, and TG were assessed. All 
patients were instructed on diet. The dosage assignment is 
listed in Table 2. The overall proportion achieving the target 
was 66.5% (125/188) with an overall mean LDL-C reduc-
tion of 35% (P  0.001). Results based on atrovastatin dose 
are listed in Table 3. The percent of change was statistically 
significant (P  0.05) for TC (–32.2%), HDL-C (–3%), 
TG (–22.2%) and non-HDL-C (–39.7%) (see Table 4). The 
adverse events that led to 2 patients withdrawing from the 
study were elevated liver enzymes (80 mg group) and slight 
muscular pain (20 mg group).
Discussion
The clinical outcome benefits of using statins in patients 
with elevated cholesterol, with significant risk for coronary 
artery disease, or with known coronary artery disease have 
been well documented over the years by numerous clinical 
trials. Despite these known beneficial effects, it often takes 
a significant period of time to reach the desired cholesterol 
lowering goal or the goal is never reached at all. The studies 
described in this review looked at alternative, aggressive 
dosing schemes to initiate statin therapy to determine if the 
cholesterol-lowering goals can be achieved and if they can 
be achieved in a shorter time frame. The proposed theory 
is that achieving the LDL-C cholesterol goal in a shorter 
period of time may have a significant impact on long-term 
outcomes.
In the studies reviewed, various dosing approaches were 
utilized. In the ATGOAL trial, the initial atorvastatin dose 
was based on a baseline LDL-C measurement and cardio-
vascular risk categories combined.15,16 This dosing approach, 
which allowed 1 dose titration at 4 weeks, led to 84.8% of 
patients reaching their LDL-C goal at the end of the 8-week 
trial. The adverse event rate in this trial was relatively low, 
with an overall atorvastatin discontinuation rate of 4% due 
to adverse events. The ATGOAL trial demonstrated a high 
achievement of the LDL-C goal in a relativity short period 
of time which was well tolerated.
The ACTFAST-1 and -2 studies utilized a dosing 
regimen in which the initial atorvastatin dose was based 
on a baseline LDL-C measurement alone.17,18 A one-
time dosage titration was allowed at 6 weeks during the 
12-week trials if a patient had not reached their LDL-C 
goal. The treatment groups were divided into statin-free 
and statin-treated. In the ACTFAST-1 trial, the percent 
of patients achieving their LDL-C goal was higher in the 
statin-free group, 79.6%, compared to the statin-treated 
patients, 58.7%.17 Interestingly, 90% of the patients achiev-
ing their LDL-C goal in the statin-free group did so with 
their initial atorvastatin dose. This suggests that if a patient 
is going to respond well in achieving their LDL-C goal, an 
initial aggressive dose will likely result in this goal being 
reached. For those who have been previously on statin 
therapy and not achieved their LDL-C goal, in most cases, 
a dose titration will not always be adequate to assist them 
in achieving their LDL-C goal. The overall incidence of 
adverse events due to atorvastatin was 12.1%, with myal-
gias and significantly elevated liver enzymes occurring in 
1% to 2% of patients. Only 1 case of elevated CPK was 
reported, demonstrating that this dosing approach was 
relatively well tolerated.
The ACTFAST-2 trial results were similar to those seen 
in the ACTFAST-1 study.18 In the statin-free treatment group, 
73.5% of patients achieved their LDL-C goal at 12 weeks, 
compared to 60.5% of patients achieving their LDL-C goal 
in the statin-treated group. Similar to the ACTFAST-1 study, 
96% of the subjects who reached their LDL-C goal did so in 
the first 6 weeks of the 12-week trial. This again suggests that, 
if a patient is going to respond to statin therapy and reach 
the desired goal, this response will typically occur early on 
in therapy, if the initial dose is aggressive. Atorvastatin was 
well tolerated in this trial, with elevated liver enzymes and 
myalgias reported in less than 1% of subjects.
Similar to the trials just mentioned, the Ducobu study 
utilized an initial LDL-C measurement to determine an ini-
tial starting dose for atorvastatin.19 In addition, a one-time 
dosage titration was allowed midway through (at 6 weeks) 
of the study. Patients were categorized as statin-naïve and 
previously treated with a statin in the analysis, with only 
the statin-naïve group being reported in the study results. In 
the statin-naïve patient group, 95.4% achieved their LDL-C 
treatment goal at 6 weeks. At 12 weeks, the percentage of 
statin-naïve patients achieving their LDL-C goal only 
increased to 96.4%. Of note, the LDL-C treatment goal in 
this trial was less than 115 mg/dL, which is higher than the 
current recommendations. These results again demonstrated 
that if patients with elevated LDL-C are being treated with 
aggressive doses of atorvastatin, the response to achieving the 
LDL-C treatment goal occurs relatively soon with the initial 
dose. Dosage titration in those not achieving their LDL-C 
with initial aggressive dosing is not likely to result in their 
achieving that LDL-C goal.Risk Management and Healthcare Policy 2010:3 9
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The Atorvastatin Study Group in Korea assessed a sliding 
scale dosing approach based on initial LDL-C measurements 
in patients with type 2 diabetes mellitus.20 This study allowed 
1 dosage titration midway through the study at 4 weeks. At 
the end of the trial, 89.3% of patients achieved their LDL-
C treatment goal. Only 9.4% of the patients in this study 
had dosage titration at 4 weeks of the study. In addition 
to evaluating the LDL-C treatment goal, the investigators 
evaluated pre- and post-values of FMD, EID, and PAI-1. 
Of these three measurements, only the post-FMD demon-
strated an improvement over the pre-FMD measurement. 
The clinical significance of these three measurements and 
how they affect long-term clinical outcomes remain to be 
determined. From a safety standpoint, atorvastatin was well 
tolerated, with increases in ALT and CK reported in a small 
percentage of patients. Similar to the other studies, very few 
study subjects required a dosage titration, supporting the 
theory that this initial aggressive dosing strategy results in 
a majority of patients achieving the LDL-C goal with the 
initial dose.
The last study reviewed looked at a sliding scale dosage 
initiation based on a baseline LDL-C measurement in statin-
naïve patients with type 2 diabetes mellitus.21 As noted in 
the trial description, dosage titration was not allowed in this 
trial. At the conclusion of this trial at 24 weeks, only 66.5% 
of the patients achieved their LDL-C treatment goal. The 
adverse event rate was very low with only 3 patients drop-
ping out due to atorvastatin adverse events. This trial is not 
consistent with the results seen in the previous trials, in that 
fewer patients in this trial achieved their LDL-C treatment 
goal with the initial statin dosage regimen. It is difficult to 
determine if this difference is due to the study population 
or relative differences in the aggressiveness of the dosage 
regimens.
When comparing these trials, several difficulties were 
encountered. The initial dosage of atorvastatin differed 
based on the initial baseline LDL-C measurement, which 
makes head-to-head comparisons of these trials and their 
results complex. An additional difficulty is that two of these 
studies included only type 2 diabetes mellitus patients, 
which may be an unfair comparison to the other studies 
that did not included a solely diabetes mellitus popula-
tion. The ATGOAL study was the only trial that included 
low and high risk patient populations.16 This trial also 
demonstrated a good rate of achievement in reaching the 
LDL-C treatment goal. Therefore, this dosing scheme 
would seem to be appropriate to implement into general 
clinical practice.
Collectively, the studies that were identified looking at 
initial dosing of statins in relationship to baseline LDL-C 
measurements demonstrated that a significant percentage of 
patients achieved their LDL-C goal during the duration of 
the study.16–21 In addition, it is noteworthy that a majority of 
patients enrolled in these trials reached their LDL-C treat-
ment goal with the initial dosage of atorvastatin. Patients 
who had higher baseline LDL-C levels, which are typically 
the most difficult to get to goal, were initially started on 
a higher dose of atorvastatin. This demonstrates that if a 
patient is going to achieve their LDL-C treatment goal, the 
response with initial dosing will be relatively quick, within 
4 to 6 weeks. The percentage of patients meeting their LDL-C 
treatment goal after dosage titration was relatively small; 
therefore for patients not achieving the LDL-C treatment 
goal with this initial dosing strategy, an alternative phar-
macologic combination or approach should be considered. 
The anticipated reductions in LDL-C levels that have been 
demonstrated in clinical trials are 38%, 46%, 51%, and 
54% reductions with 10 mg, 20 mg, 40 mg, and 80 mg of 
atorvastatin, respectively.8
In addition to the primary goal of these trials, several of 
the trials evaluated secondary goals.16–21 Total cholesterol, 
TG, HDL-C, TC/HDL-C ratio, Apo-B, and non-HDL-C 
were utilized as secondary goals in these trials. Reduc-
tions in TC, TG, TC/HDL-C ratio, Apo-B, and non-HDL-C 
were observed in the trials assessing these outcomes. The 
effect in these studies of these dosing schemes on HDL-C 
was mixed.
One of the major limitations of the studies was that they 
were relatively short, ranging from 8 to 24 weeks.16–21 Since 
these trials were short, long-term outcomes such as reduced 
coronary events, mortality and other long-term outcome 
measures could not be assessed. Therefore, these studies were 
limited to using LDL-C lowering and other cholesterol profile 
markers as their major outcomes to determine if these dosing 
approaches were indeed effective in getting more people to 
goal in a shorter time. Based on the studies reviewed, it is 
evident that a larger percentage of patients achieved their 
LDL-C treatment goal in a time compared to traditional 
initiation and dosage titration of statin therapy. However, 
it remains to be seen whether or not this more aggressive 
approach of initiating statin therapy has any additional impact 
on long-term clinical outcomes.
A potential safety concern with this approach to the 
initiation of statin therapy is the possibility of a higher inci-
dence of significant adverse effects. In the studies reviewed, 
the rate of adverse effects was relatively low and not higher Risk Management and Healthcare Policy 2010:3 0
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than expected with traditional dosing of starting at a low 
dose and slowly titrating the dose up until the treatment goal 
is achieved. Choosing a more aggressive starting dose of a 
statin does not appear to cause a significantly higher rate of 
adverse reactions.
An additional limitation was that all of the studies iden-
tified and reviewed for initial aggressive dosing used only 
atorvastatin. It may not be appropriate to assume that this 
aggressive initial dosing will be as safe and efficacious with 
other statins. Studies assessing aggressive initial dosing 
of other statins should be conducted instead of trying to 
extrapolate these data to other drugs in this class.
Although the main focus of this review is on the statin 
therapy and dosing algorithm, it is important to remember the 
importance of diet therapy in patients with hyperlipidemia 
and coronary heart disease. As noted in the review of these 
trials, appropriate diet therapy was utilized, and clinicians 
should incorporate an appropriate diet as a part of the treat-
ment approach.
It is difficult to take these studies as a whole and incor-
porate into practice an approach to initiating statin therapy. 
The main reasons this is difficult are that these trials did 
not utilize the same criteria and approach for determining 
the initial statin dose, and that some of the trials included 
patients who were already being treated with a statin.
The ATGOAL trial utilized a relatively complex approach 
to initiating statin therapy compared to the other studies that 
were identified and reviewed. In addition to utilizing the 
baseline LDL-C measurement, subjects were risk stratified 
based on their CHD risk, and then the initial statin dose 
was determined taking both of these factors into account. 
It could be argued that this approach is too complex in 
practice for the general clinical setting. However, this 
approach would likely be very useful in a specialized 
setting in which initiation of statin therapy was the major 
focus of the clinical practice, for example, a specialized 
lipid clinic.
Of the trials identified and reviewed, the dosing initia-
tion algorithm that appeared to be the most user friendly 
for general practitioners as well as effective in achieving 
the LDL-C goal was that utilized in the ACTFAST-1 and -2 
trials.17,18 Specifically, the “statin-free” treatment algorithm 
could be utilized and incorporated into most clinical settings 
and practices. This algorithm demonstrated achievement 
of the LDL-C goal in approximately 70% to 80% of the 
subjects by the end of the 12-week trial. In addition, this 
dosing approach was well tolerated, with minimal adverse 
effects reported.
Conclusion
Cardiovascular disease remains the leading cause of death in 
the world and has a significant impact on healthcare systems. 
Historically, the utilization of statins in the cardiovascular 
disease population has demonstrated a significant impact on 
clinical outcomes, specifically reduced mortality and reduced 
progression of cardiovascular disease and cardiovascular 
disease complications. Despite this evidence, many patients 
with cardiovascular disease either do not receive statin 
therapy, or are on suboptimal doses, as the medications are 
not uptitrated to achieve the treatment goals. The clinical 
trials reviewed assessed the efficacy and safety of using 
an initial dosing strategy determined by baseline LDL-C 
measurements to achieve treatment goals quicker. The stud-
ies demonstrated that some of the dosing strategies worked 
very well in reaching cholesterol treatment goals and were 
also well tolerated. The question that remains unanswered is 
what impact does achieving treatment goals sooner have on 
long-term clinical outcomes. Initial dosing of statin therapy 
with an algorithm utilizing a baseline LDL-C measurement 
appears to be a safe and effective option for starting a patient 
on statin therapy.
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